Skip to content

Author

Minghua Xiang

1 paper indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Aug 2026

PARP Inhibitors plus Anlotinib as Bridging Therapy for Armored CAR‐T Cells in Ovarian Cancer Enhances Infiltration and Antitumor Efficacy

The findings support a clinically actionable bridging therapy with translational potential for potentiating CAR‐T cell therapy in ovarian cancer and highlight bridging therapy as a translational approach to improve CAR‐T cell access and efficacy in solid tumors.

Hua-Yi Li, Minghua Xiang, Qiuyang Xu et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.